Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ibrutinib in the real world patient: many lights and some shades.

Literature DB >> 27903711

Ibrutinib in the real world patient: many lights and some shades.

Paolo Ghia¹, Antonio Cuneo².

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2016 PMID： 27903711 PMCID： PMC5479615 DOI： 10.3324/haematol.2016.155986

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

20 in total

1. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: B Eichhorst; T Robak; E Montserrat; P Ghia; P Hillmen; M Hallek; C Buske
Journal: Ann Oncol Date: 2015-09 Impact factor: 32.976

2. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors: Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal: Blood Date: 2015-10-20 Impact factor: 22.113

3. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.

Authors: Yair Herishanu; Neta Goldschmidt; Osnat Bairey; Rosa Ruchlemer; Riva Fineman; Naomi Rahimi-Levene; Lev Shvidel; Tamar Tadmor; Aviv Ariel; Andrea Braester; Mika Shapiro; Erel Joffe; Aaron Polliack
Journal: Haematologica Date: 2015-02-06 Impact factor: 9.941

4. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

Authors: Susan O'Brien; Jeffrey A Jones; Steven E Coutre; Anthony R Mato; Peter Hillmen; Constantine Tam; Anders Österborg; Tanya Siddiqi; Michael J Thirman; Richard R Furman; Osman Ilhan; Michael J Keating; Timothy G Call; Jennifer R Brown; Michelle Stevens-Brogan; Yunfeng Li; Fong Clow; Danelle F James; Alvina D Chu; Michael Hallek; Stephan Stilgenbauer
Journal: Lancet Oncol Date: 2016-09-13 Impact factor: 41.316

Review 5. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.

Authors: Michael Hallek
Journal: Am J Hematol Date: 2015-05 Impact factor: 10.047

6. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Authors: Mohammed Z H Farooqui; Janet Valdez; Sabrina Martyr; Georg Aue; Nakhle Saba; Carsten U Niemann; Sarah E M Herman; Xin Tian; Gerald Marti; Susan Soto; Thomas E Hughes; Jade Jones; Andrew Lipsky; Stefania Pittaluga; Maryalice Stetler-Stevenson; Constance Yuan; Yuh Shan Lee; Lone B Pedersen; Christian H Geisler; Katherine R Calvo; Diane C Arthur; Irina Maric; Richard Childs; Neal S Young; Adrian Wiestner
Journal: Lancet Oncol Date: 2014-12-31 Impact factor: 41.316

7. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors: John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal: Blood Date: 2015-02-19 Impact factor: 22.113

8. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.

Authors: Milena Sant; Claudia Allemani; Carmen Tereanu; Roberta De Angelis; Riccardo Capocaccia; Otto Visser; Rafael Marcos-Gragera; Marc Maynadié; Arianna Simonetti; Jean-Michel Lutz; Franco Berrino
Journal: Blood Date: 2010-07-27 Impact factor: 22.113

9. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.

Authors:
Journal: Haematologica Date: 2016-10-18 Impact factor: 9.941

10. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors: John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245

7 in total

Review 1. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.

Authors: Caspar da Cunha-Bang; Carsten Utoft Niemann
Journal: Drugs Date: 2018-11 Impact factor: 9.546

2. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.

Authors: K Uminski; K Brown; O Bucher; I Hibbert; D H Dhaliwal; J B Johnston; M Geirnaert; D E Dawe; V Banerji
Journal: Curr Oncol Date: 2019-10-01 Impact factor: 3.677

3. Reduced Dose Ibrutinib Due to Financial Toxicity in CLL.

Authors: Deepesh P Lad; Pankaj Malhotra; Alka Khadwal; Gaurav Prakash; Arihant Jain; Subhash Varma
Journal: Indian J Hematol Blood Transfus Date: 2018-09-08 Impact factor: 0.900

4. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Authors: Antonio Cuneo; George Follows; Gian Matteo Rigolin; Alfonso Piciocchi; Alessandra Tedeschi; Livio Trentin; Angeles Medina Perez; Marta Coscia; Luca Laurenti; Gerardo Musuraca; Lucia Farina; Alfredo Rivas Delgado; Ester Maria Orlandi; Piero Galieni; Francesca Romana Mauro; Carlo Visco; Angela Amendola; Atto Billio; Roberto Marasca; Annalisa Chiarenza; Vittorio Meneghini; Fiorella Ilariucci; Monia Marchetti; Stefano Molica; Francesca Re; Gianluca Gaidano; Marcos Gonzalez; Francesco Forconi; Stefania Ciolli; Agostino Cortelezzi; Marco Montillo; Lukas Smolej; Anna Schuh; Toby A Eyre; Ben Kennedy; Kris M Bowles; Marco Vignetti; Javier de la Serna; Carol Moreno; Robin Foà; Paolo Ghia
Journal: Haematologica Date: 2018-04-19 Impact factor: 9.941

5. Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Authors: Antonio Cuneo; Robin Foà
Journal: Mediterr J Hematol Infect Dis Date: 2019-03-01 Impact factor: 2.576

6. Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.

Authors: Francesca Romana Mauro; Francesca Paoloni; Stefano Molica; Gianluigi Reda; Livio Trentin; Paolo Sportoletti; Monia Marchetti; Daniela Pietrasanta; Roberto Marasca; Gianluca Gaidano; Marta Coscia; Caterina Stelitano; Donato Mannina; Nicola Di Renzo; Fiorella Ilariucci; Anna Marina Liberati; Lorella Orsucci; Francesca Re; Monica Tani; Gerardo Musuraca; Daniela Gottardi; Pier Luigi Zinzani; Alessandro Gozzetti; Annalia Molinari; Massimo Gentile; Annalisa Chiarenza; Luca Laurenti; Marzia Varettoni; Adalberto Ibatici; Roberta Murru; Valeria Ruocco; Ilaria Del Giudice; Maria Stefania De Propris; Irene Della Starza; Sara Raponi; Mauro Nanni; Paola Fazi; Antonino Neri; Anna Guarini; Gian Matteo Rigolin; Alfonso Piciocchi; Antonio Cuneo; Robin Foà
Journal: Cancers (Basel) Date: 2021-12-31 Impact factor: 6.639

7. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.

Authors: Antonio Cuneo; Anthony R Mato; Gian Matteo Rigolin; Alfonso Piciocchi; Massimo Gentile; Luca Laurenti; John N Allan; John M Pagel; Danielle M Brander; Brian T Hill; Allison Winter; Nicole Lamanna; Constantine S Tam; Ryan Jacobs; Frederick Lansigan; Paul M Barr; Mazyar Shadman; Alan P Skarbnik; Jeffrey J Pu; Alison R Sehgal; Stephen J Schuster; Nirav N Shah; Chaitra S Ujjani; Lindsey Roeker; Ester Maria Orlandi; Atto Billio; Livio Trentin; Martin Spacek; Monia Marchetti; Alessandra Tedeschi; Fiorella Ilariucci; Gianluca Gaidano; Michael Doubek; Lucia Farina; Stefano Molica; Francesco Di Raimondo; Marta Coscia; Francesca Romana Mauro; Javier de la Serna; Angeles Medina Perez; Isacco Ferrarini; Giuseppe Cimino; Maurizio Cavallari; Rosalba Cucci; Marco Vignetti; Robin Foà; Paolo Ghia
Journal: Cancer Med Date: 2020-09-24 Impact factor: 4.452

7 in total